4th Cell Therapy for Autoimmune Disease Summit
As cell therapy for autoimmune disease transitions from breakthrough clinical case studies to broad clinical validation, developers are racing to overcome challenges around safety, scalability, durability of response, and patient access while advancing the next generation of immune reset therapies.
In this context, the 4th Cell Therapy for Autoimmune Disease Summit (December 1-3, 2026) returns to Philadelphia, PA, bringing together biotech, pharma, academic, and clinical leaders working across autologous, allogeneic, and in vivo cell therapy approaches to accelerate the development of transformative treatments for autoimmune diseases.
Organizations including Artiva Biotherapeutics, Cabaletta Bio, PolTREG, Moderna, Mesoblast, Sail Biomedicines, CPTx, Kite Pharma, Overland Therapeutics, and the University of Pennsylvania are confirmed to participate, sharing the latest scientific, clinical, and commercial insights shaping the field.
Over three days, attendees will gain exclusive access to the latest advances in autoimmune cell therapy development, spanning preclinical innovation, translational research, clinical trial progress, manufacturing strategies, and commercialization considerations. The event features two dedicated content tracks focused on Preclinical Development & Translation and Clinical Development, providing a comprehensive view of the rapidly evolving autoimmune cell therapy landscape.
Expect to:
- Analyze the latest CAR-T, NK, and Treg clinical data to understand how autoimmune cell therapies are reshaping treatment paradigms
- Explore next-generation and in vivo cell therapy platforms designed to improve safety, durability, scalability, and patient access
- Learn best practices for clinical development, trial design, and regulatory strategy from leading autoimmune cell therapy innovators
- Connect with 100+ biotech, pharma, academic, and clinical leaders to discuss commercialization, adoption, and the future of immune reset therapies
The summit will also showcase the latest developments across key autoimmune indications, including lupus, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, stiff person syndrome, and rare autoimmune diseases, providing attendees with actionable insights to support clinical and commercial success.
For the complete agenda, speaker faculty, and event information, visit the website here: https://ter.li/anilpy9t